1
|
Amore E, Manca ML, Ferraro M, Valenti D, La Parola V, Di Vincenzo S, Gjomarkaj M, Giammona G, Bondì ML, Pace E. Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment. Int J Pharm 2019; 562:351-358. [PMID: 30935915 DOI: 10.1016/j.ijpharm.2019.03.059] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 03/25/2019] [Accepted: 03/27/2019] [Indexed: 01/12/2023]
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.
Collapse
Affiliation(s)
- Erika Amore
- Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy; Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Maria Letizia Manca
- Dipartimento Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, Università degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Maria Ferraro
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Donatella Valenti
- Dipartimento Scienze della Vita e dell'Ambiente, Sezione Scienze del Farmaco, Università degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
| | - Valeria La Parola
- Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Serena Di Vincenzo
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Mark Gjomarkaj
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Gaetano Giammona
- Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy
| | - Maria Luisa Bondì
- Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
| | - Elisabetta Pace
- Istituto di Biomedicina e Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy.
| |
Collapse
|